DMK Pharmaceuticals (DMK Pharmaceuticals) Cash And Cash Equivalents : $6.66 Mil (As of Sep. 2023)

View and export this data going back to 1995. Start your Free Trial

What is DMK Pharmaceuticals Cash And Cash Equivalents?

DMK Pharmaceuticals's quarterly cash and cash equivalents declined from Mar. 2023 ($3.10 Mil) to Jun. 2023 ($0.64 Mil) but then increased from Jun. 2023 ($0.64 Mil) to Sep. 2023 ($6.66 Mil).

DMK Pharmaceuticals's annual cash and cash equivalents increased from Dec. 2020 ($6.75 Mil) to Dec. 2021 ($23.22 Mil) but then declined from Dec. 2021 ($23.22 Mil) to Dec. 2022 ($1.08 Mil).

DMK Pharmaceuticals Cash And Cash Equivalents Historical Data

The historical data trend for DMK Pharmaceuticals's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMK Pharmaceuticals Cash And Cash Equivalents Chart

DMK Pharmaceuticals Annual Data

Trend

Mar13

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash And Cash Equivalents

Get a 7-Day Free Trial

19.27

8.81

6.75

23.22

1.08

DMK Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash And Cash Equivalents	Get a 7-Day Free Trial															2.42	1.08	3.10	0.64	6.66

DMK Pharmaceuticals Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

DMK Pharmaceuticals (OTCPK:DMKPQ) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

DMK Pharmaceuticals Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (OTCPK:DMKPQ) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130

Website

https://www.adamispharmaceuticals.com

DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

Executives

Dorbin John W. Jr.	officer: General Counsel	C/O ARCIMOTO, INC., 2034 WEST 2ND AVENUE, EUGENE OR 97402
Seth Cohen	officer: CFO	C/O NEWTEK BUSINESS SERVICES,INC, 1440 BROADWAY, NEW YORK NY 10018
Ebrahim Versi	director, officer: CEO	11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Jannine Versi	director	11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Vickie S Reed	director	TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David J. Marguglio	director	2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Carlo Dennis J Phd	director, 10 percent owner, officer: President/CEO	PO BOX 1176, RANCHO SANTA FE CA 92067
Ronald B. Moss	officer: Chief Medical Officer	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
David C. Benedicto	officer: Chief Financial Officer	11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Meera J. Desai	director	1682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Robert O Hopkins	officer: Chief Financial Officer	2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Karen K. Daniels	officer: Vice President of Operations	11455 EL CAMINO REAL, SUITE 310, SAN DIEGO CA 92130
Howard C Birndorf	director	C/O NANOGEN INC, 10398 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Roshawn A. Blunt	director	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Richard C Williams	director	26001 OSPREY NEST COURT, BONITA SPRINGS FL 34134